REFERENCES
1. Ducamp S, Fleming MD. The molecular genetics of sideroblastic anemia.Blood . 2019;133(1):59-69. doi:10.1182/blood-2018-08-815951
2. Rodriguez-Sevilla JJ, Calvo X, Arenillas L. Causes and
Pathophysiology of Acquired Sideroblastic Anemia. Genes .
2022;13(9):1562. doi:10.3390/genes13091562
3. Rudek MA, Horne M, Figg WD, et al. Reversible sideroblastic anemia
associated with the tetracycline analogue COL-3. Am J Hematol .
2001;67(1):51-53. doi:10.1002/ajh.1076
4. Blair HA. Dolutegravir/Rilpivirine: A Review in HIV-1 Infection.Drugs . 2018;78(16):1741-1750. doi:10.1007/s40265-018-1005-4
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the
probability of adverse drug reactions. Clin Pharmacol Ther .
1981;30(2):239-245. doi:10.1038/clpt.1981.154
6. WHO-CDS-HIV-19.15-eng.pdf. Accessed July 21, 2023.
https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf
7. Messiaen P, Wensing AMJ, Fun A, Nijhuis M, Brusselaers N,
Vandekerckhove L. Clinical Use of HIV Integrase Inhibitors: A Systematic
Review and Meta-Analysis. PLOS ONE . 2013;8(1):e52562.
doi:10.1371/journal.pone.0052562
8. Craigie R, Bushman FD. HIV DNA Integration. Cold Spring Harb
Perspect Med . 2012;2(7):a006890. doi:10.1101/cshperspect.a006890
9. Kandel CE, Walmsley SL. Dolutegravir – a review of the pharmacology,
efficacy, and safety in the treatment of HIV. Drug Des Devel
Ther . 2015;9:3547-3555. doi:10.2147/DDDT.S84850
10. Curtis L, Nichols G, Stainsby C, et al. Dolutegravir: Clinical and
Laboratory Safety in Integrase Inhibitor–Naive Patients. HIV Clin
Trials . 2014;15(5):199-208. doi:10.1310/hct1505-199
11. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts
(RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis,
risk-stratification, and management. Am J Hematol .
2017;92(3):297-310. doi:10.1002/ajh.24637
12. Abu-Zeinah G, DeSancho MT. Understanding Sideroblastic Anemia: An
Overview of Genetics, Epidemiology, Pathophysiology and Current
Therapeutic Options. J Blood Med . 2020;11:305-318.
doi:10.2147/JBM.S232644
13. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the
World Health Organization (WHO) classification of myeloid neoplasms and
acute leukemia: rationale and important changes. Blood .
2009;114(5):937-951. doi:10.1182/blood-2009-03-209262
14. Tenner S, Rollhauser C, Butt F, Gonzalez P. Sideroblastic anemia: A
diagnosis to consider in alcoholic patients. Postgrad Med .
1992;92(7):147-150. doi:10.1080/00325481.1992.11701538
15. Simon SR, Branda RF, Tindle BH, Burns SL. Copper deficiency and
sideroblastic anemia associated with zinc ingestion. Am J
Hematol . 1988;28(3):181-183. doi:10.1002/ajh.2830280310
16. Beck EA, Ziegler G, Schmid R, Lüdin H. Reversible Sideroblastic
Anemia Caused by Chloramphenicol. Acta Haematol . 2009;38(1):1-10.
doi:10.1159/000208994
17. Willekens C, Dumezy F, Boyer T, et al. Linezolid induces ring
sideroblasts. Haematologica . 2013;98(11):e138-e140.
doi:10.3324/haematol.2013.092395